Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

A.OVERVIEW

This is a 26 week study examining the ability of paroxetine (Paxil) to prevent the development of depression and neurotoxicity in patients receiving either 3 million units of subcutaneous IFN(interferon-alpha-2b) 3 times/week (plus ribavirin, 1000-1200 mg/d)) or PEG (polyethylene glycol) interferon-alpha-2b (1.5 micrograms/kg one time a week) and ribavirin (800 to 1,400 mg a day) for chronic hepatitis C (CHC). The IFN plasma half life (t1/2 of 24 to 34 hours) of PEG, a CHC treatment recently approved by the FDA, is significantly prolonged allowing for once a week dosing. Studies indicate that the side effect profile of the two forms of IFN-alpha treatment are very similar. CHC patients will be screened for study eligibility, and a total of 100 CHC patients between the ages of 18 and 65 years old will be enrolled across three sites (30 at Emory site and a combination of 30 from the University of Pennsylvania, Rush-Presbyterian-Saint Lukes Medical Center in Chicago and Montefiore Medical Center in New York.) Two weeks prior to treatment with subcutaneous IFN-alpha-2b, patients who meet inclusion and exclusion criteria will be stratified on the basis of a history of major depression and then randomly assigned to paroxetine or placebo in double blind fashion.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Treatments: Interferons; Paroxetine

Criteria

Inclusion Criteria:

• age 18-65 years including males, females and minorities

• serum positive for either anti-HCV antibodies or HCV-RNA positive by PCR

• compensated liver disease with the following minimum hematologic and biochemical criteria: hemoglobin 3 g/dl for males; 12 g/dl for females, white blood cell count > 3,000/mm3, neutrophil count >1,5000/mm3, platelets > 100,000/mm3, prothrombin time 2 seconds prolonged compared to control, or equivalent INR ratio, albumin stable and within normal limits, serum creatinine within normal limits, thyroid-stimulating hormone (TSH) within normal limits, direct bilirubin 0.3 mg/dl or within 20% of upper limit of normal (ULN) for local laboratory, indirect bilirubin 0.8 mg/dl or within 20% of ULN for local laboratory, fasting blood sugar 115 mg/dl or within 20% of ULN for non-diabetic patients

• serum hepatitis B surface antigen (HbsAg) negative, antinuclear antibodies (ANA) 1:320

• normal pre-therapy ocular examination if a history of diabetes or hypertension

• hemoglobin A1C <8.5% if a history of diabetes

• negative pregnancy test for women of childbearing potential, and consent to adhere to adequate contraception or monogamous relationship with a male partner who has had a vasectomy during the treatment period and for 6 months after discontinuation of therapy

• not breast feeding

• documentation and confirmation of adequate contraception in sexually active males

• free from all psychotropic medications for a minimum of 14 days prior to baseline visit (8 weeks for fluoxetine)

Exclusion Criteria:

• actively meet criteria for major depression within the past six months

• active, effective treatment of depression with an antidepressant within the past three months

• meet criteria for schizophrenia or bipolar disorder (mania) past or present

• actively meet DSM IV criteria for substance abuse/dependence within the past six months

• psychotropic medications within 14 days prior to baseline visit (8 weeks for fluoxetine)

• evidence of untreated or poorly controlled endocrine, cardiovascular, hematological, renal, or neurological disease

• evidence of decompensated liver disease (such as a history or presence of ascites, bleeding varices, spontaneous encephalopathy)

• history of CNS trauma or active seizure disorder requiring medication

• any cause for liver disease other than chronic hepatitis C, such as co-infection with hepatitis B virus and/or human immunodeficiency virus, hemochromatosis, or Wilson's disease

• prior treatment with other (other than IFN-alpha or ribavirin) immunomodulatory drugs, including corticosteroids within 6 months of entry into protocol

• clinical gout

• known hypersensitivity to alpha interferon or ribavirin

• hemoglobinopathies (e.g. thalassemia)

• a positive pregnancy test

• clinically significant retinal abnormalities

• organ transplants

• a score of <24 on the Mini Mental Status Exam (MMSE)

• prior history of severe adverse events associated with paroxetine

• any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with participating in or completing the protocol